74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Baxter International Inc
Closed
SectorHealthcare
30.39 2.46
Overview
Share price change
24h
Min
29.42
Max
30.46
Income | -637M -488M |
|---|---|
Sales | 54M 2.8B |
P/E Sector Avg | 124.8 57.333 |
EPS | 0.58 |
Dividend yield | 2.35 |
Profit margin | -17.726 |
Employees | 38,000 |
EBITDA | -475M -176M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +25.29% upside |
Dividend yield Sector Avg | 2.35% 2.63% |
|---|---|
Next Earnings | 1 May 2025 |
Next Dividend date | 30 Jun 2025 |
Next Ex Dividend date | 29 May 2025 |
Market Cap | -1.8B 15B |
|---|---|
Previous open | 27.93 |
Previous close | 30.39 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Baxter International Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Baxter International Inc Forecast
Price Target
By TipRanks
25.29% upside
12 Months Forecast
Average 38.1 USD 25.29%
High 44 USD
Low 30 USD
Based on 11 Wall Street analysts offering 12 month price targets forBaxter International Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Baxter International Inc
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
